Baxter's Robert Parkinson - CEO Pay
Baxter - Robert Parkinson
Total Compensation: $17.6M
2007 Revenue: $11.3B
2006 Revenue: $10.4B
Change: 8.6%
Details: Parkinson's $17.6 million haul was driven primarily by strong company and individual performance in 2007 and 2006. According to the company's proxy statement, Parkinson's compensation "reflects the role he has played in the turnaround of the company since his arrival in 2004." Parkinson gained $1.29M in base salary, $3.75M in stock option awards, and $2.28 in additional pension.
Baxter News:
Baxter: Fake heparin predated API
Baxter recalls heparin on adverse events
Comments
Post new comment
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges
Click here to get the FiercePharma email newsletter for FREE!
Be the first to comment